Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 14/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13972844 | 0.84 | MEN1 (0.72) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL14452035 | 0.83 | MEN1 (0.70) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL14438321 | 0.83 | MEN1 (0.70) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL13958930 | 0.83 | MEN1 (0.70) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL12770960 | 0.81 | MEN1 (0.68) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL11250227 | 0.79 | MEN1 (0.66) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL2216798 | 0.79 | MEN1 (0.65) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL11244177 | 0.79 | MEN1 (0.65) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL12844535 | 0.78 | NPC1 (0.68) | MEN1KMT2ANPC1RAB9ATSHR | |
| SCHEMBL23046929 | 0.77 | MEN1 (0.62) | MEN1KMT2ANPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | MEN1 2811/4885KMT2A 3141/4885NPC1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.